Novavax (NASDAQ:NVAX) stock hasn’t gotten a booster shot in 2023 yet, but it might end up recovering and even rallying before the year is over. I am bullish on NVAX stock because it’s the underdog vaccine stock that people are ignoring today but might obsess over soon.
Headquartered in Maryland, Novavax has been manufacturing a variety of vaccines since the 1980s. It’s somewhere between a small-cap and a mid-cap company (one might call it a “smid-cap”), with a market capitalization of ~$798 million.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased